Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

R 95867

Known as: R-95867 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
The in vitro activity of R-95867, the active metabolite of a new oral carbapenem, CS-834, was compared with those of DU-6859a… Expand
  • table I
  • table I
  • table II
Is this relevant?
2000
2000
We compared the in vitro antibacterial activity of DU-6681a against Gram-positive and Gram-negative bacteria with that of R-95867… Expand
Is this relevant?
1999
1999
CS-834, a carbapenem antibiotic from Sankyo, is in phase II clinical trials for respiratory and urinary tract infections. It is… Expand
Is this relevant?
1998
1998
CS-834 is a prodrug of the carbapenem R-95867, developed by Sankyo Co., Ltd., Tokyo, Japan. To investigate the possibility that… Expand
Is this relevant?
1998
1998
We evaluated the in-vitro and in-vivo antibacterial activities of R-95867 and CS-834, a new oral carbapenem which is an ester… Expand
  • figure 1
  • table II
  • figure 2
  • table III
  • table IV
Is this relevant?
1997
1997
CS-834 is a novel oral carbapenem antibiotic. This compound is an ester-type prodrug of the active metabolite R-95867. The… Expand
  • table 1
  • figure 2
  • table 2
  • table 3
  • table 4
Is this relevant?
1997
1997
CS-834, (+)-[pivaloyloxymethyl (4R,5S,6S)-6-[(R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(R)-5-oxopyrroli din-3-yl]thio]-1-azabicyclo… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?